Research Analysts’ Weekly Ratings Changes for Humana (HUM)

Several brokerages have updated their recommendations and price targets on shares of Humana (NYSE: HUM) in the last few weeks:

  • 11/12/2026 – Humana had its “hold (c)” rating reaffirmed by Weiss Ratings.
  • 11/12/2026 – Humana had its price target raised by Wells Fargo & Company from $502.00 to $602.00. They now have an “overweight” rating on the stock.
  • 11/11/2026 – Humana had its price target raised by TD Cowen from $370.00 to $430.00. They now have a “hold” rating on the stock.
  • 11/10/2026 – Humana was upgraded by Zacks Research from “hold” to “strong-buy”.
  • 11/10/2026 – Humana had its price target raised by JPMorgan Chase & Co. from $393.00 to $484.00. They now have a “neutral” rating on the stock.
  • 11/9/2026 – Humana had its price target raised by Piper Sandler from $463.00 to $526.00. They now have an “overweight” rating on the stock.
  • 11/9/2026 – Humana had its price target raised by Barclays from $582.00 to $587.00. They now have an “overweight” rating on the stock.
  • 11/9/2026 – Humana had its price target raised by Guggenheim from $471.00 to $521.00. They now have a “buy” rating on the stock.
  • 11/9/2026 – Humana had its price target raised by Cantor Fitzgerald from $460.00 to $495.00. They now have an “overweight” rating on the stock.
  • 11/9/2026 – Humana was upgraded by Wall Street Zen from “hold” to “buy”.
  • 11/6/2026 – Humana had its “outperform” rating reaffirmed by Raymond James Financial.
  • 11/6/2026 – Humana had its “buy” rating reaffirmed by Jefferies Financial Group. They now have a $420.00 price target on the stock.
  • 11/1/2026 – Humana was downgraded by Wall Street Zen from “buy” to “hold”.
  • 10/24/2026 – Humana was upgraded by Wall Street Zen from “hold” to “buy”.
  • 10/13/2026 – Humana had its price target raised by Mizuho from $468.00 to $495.00. They now have an “outperform” rating on the stock.
  • 10/12/2026 – Humana had its price target raised by Oppenheimer from $475.00 to $525.00. They now have an “outperform” rating on the stock.
  • 10/12/2026 – Humana had its price target raised by UBS Group from $405.00 to $495.00. They now have a “neutral” rating on the stock.
  • 10/12/2026 – Humana had its price target raised by Truist Financial from $415.00 to $475.00. They now have a “hold” rating on the stock.
  • 10/12/2026 – Humana was upgraded by Raymond James Financial from “market perform” to “outperform”. They now have a $520.00 price target on the stock.
  • 10/9/2026 – Humana was upgraded by Morgan Stanley from “underweight” to “overweight”.
  • 10/9/2026 – Humana was upgraded by Monness Crespi & Hardt to “buy”.
  • 10/9/2026 – Humana is now covered by Citigroup. They set a “buy” rating on the stock.
  • 10/9/2026 – Humana had its price target raised by Oppenheimer from $405.00 to $475.00. They now have an “outperform” rating on the stock.
  • 10/9/2026 – Humana had its price target raised by Barclays from $515.00 to $582.00. They now have an “overweight” rating on the stock.
  • 10/9/2026 – Humana was given a new $596.00 price target by UBS Group.
  • 10/9/2026 – Humana was upgraded by Robert W. Baird from “neutral” to “outperform”. They now have a $596.00 price target on the stock, up from $390.00.
  • 10/9/2026 – Humana was upgraded by Robert W. Baird from “neutral” to “outperform”. They now have a $596.00 price target on the stock, up from $390.00.
  • 10/7/2026 – Humana was given a new $460.00 price target by Raymond James Financial.
  • 10/7/2026 – Humana was upgraded by Cantor Fitzgerald from “neutral” to “overweight”. They now have a $460.00 price target on the stock, up from $300.00.
  • 9/27/2026 – Humana was downgraded by Wall Street Zen from “buy” to “hold”.
  • 9/25/2026 – Humana was upgraded by Barclays from “equal weight” to “overweight”. They now have a $515.00 price target on the stock, up from $407.00.
  • 9/19/2026 – Humana was upgraded by Wall Street Zen from “hold” to “buy”.

Humana Trading Up 0.1%

Shares of HUM opened at $450.38 on Monday. The stock’s fifty day simple moving average is $408.53 and its 200-day simple moving average is $316.91. The firm has a market capitalization of $54.09 billion, a PE ratio of 43.81, a price-to-earnings-growth ratio of 2.14 and a beta of 0.65. Humana Inc. has a 12-month low of $163.11 and a 12-month high of $456.50. The company has a quick ratio of 1.65, a current ratio of 1.65 and a debt-to-equity ratio of 0.61.

Humana (NYSE:HUM – Get Free Report) last announced its quarterly earnings data on Friday, November 6th. The insurance provider reported ($0.70) EPS for the quarter, topping analysts’ consensus estimates of ($1.00) by $0.30. The firm had revenue of $41.16 billion during the quarter, compared to analyst estimates of $40.87 billion. Humana had a return on equity of 8.50% and a net margin of 0.81%. The company’s revenue was up 26.1% on a year-over-year basis. During the same period last year, the company earned $3.24 earnings per share. Humana has set its FY 2026 guidance at 9.500- EPS. As a group, research analysts predict that Humana Inc. will post 9.66 earnings per share for the current year.

Humana Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, January 29th. Stockholders of record on Thursday, December 24th will be given a dividend of $0.8850 per share. The ex-dividend date is Thursday, December 24th. This represents a $3.54 annualized dividend and a dividend yield of 0.8%. Humana’s payout ratio is currently 34.44%.

Insider Buying and Selling at Humana

In related news, insider Joseph Ventura sold 5,495 shares of the business’s stock in a transaction that occurred on Monday, November 9th. The shares were sold at an average price of $433.85, for a total transaction of $2,384,005.75. Following the completion of the sale, the insider directly owned 21,910 shares of the company’s stock, valued at $9,505,653.50. The trade was a 20.05% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. 0.20% of the stock is currently owned by company insiders.

Humana Inc. is a U.S. health and wellness company that provides health insurance and healthcare services. Its insurance offerings include Medicare Advantage, Medicare Supplement and prescription drug plans, as well as Medicaid and employer-sponsored plans. The company also provides care through CenterWell, its healthcare services brand, which includes primary care, home health and pharmacy services. Its insurance and care offerings are available in markets across the United States, with availability varying by product and location.

Read More

Receive News & Ratings for Humana Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana Inc and related companies with MarketBeat.com's FREE daily email newsletter.